GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy
- PMID: 21278772
- DOI: 10.1038/nrclinonc.2010.219
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy
Abstract
Randomized phase III trials have established new standards of care for advanced biliary cancer, HER2-positive advanced gastric or gastro-esophageal junction cancer, and preliminarily, for metastatic pancreatic cancer. There is now a validated predictive biomarker to guide use of adjuvant chemotherapy in patients with stage II colon cancer.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
